Evidence map›Paper›PMID 42168240›Full record

ArticleScientific reports2026

Using an RNA binding protein to detect mRNA on lipid nanoparticles.

Meagan McMahon, Hareth Al-Wassiti, Kirsten Vandenberg, Karen L Laurie, Steven Rockman

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Meagan McMahonCSL Seqirus Ltd, Parkville, Australia. Meagan.mcmahon@seqirus.com.
Hareth Al-WassitiDepartment of Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.
Kirsten VandenbergCSL Seqirus Ltd, Parkville, Australia.
Karen L LaurieCSL Seqirus Ltd, Parkville, Australia.
Steven RockmanCSL Seqirus Ltd, Parkville, Australia. Steven.rockman@seqirus.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of lipid nanoparticles (LNP) to deliver nucleic acid has emerged as a promising technology for vaccines and gene therapy. The efficiency of delivery relies on the ability of lipid chemistry to encapsulate the nucleic acid within its shell rather than exposing the nucleic acid on the surface of the LNP. To develop an encapsulation assay to detect the amount of mRNA on the surface or internalised in a LNP, we utilised a viral RNA binding protein, a monoclonal antibody to this RNA binding protein and a magnetic bead arrangement to determine the encapsulation efficiency of the RNA in a standard RNA LNP formulation. By manipulating the components, we could determine the efficiency of RNA incorporation within the LNP. We suggest that this approach will be useful in optimising the delivery of nucleic acids by LNPs and their applications.

Indexed as

LipidsNanoparticlesRNA-Binding ProteinsRNA, MessengerAntibodies, MonoclonalLiposomesAntibodies, MonoclonalLipid NanoparticlesLipidsLiposomesRNA-Binding ProteinsRNA, Messenger

Identifiers

PMID42168240
PMCPMC13402288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.